Zerlasiran
Product Specifications
UNSPSC Description
Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer[1].
Target Antigen
Apolipoprotein; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics;Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/zerlasiran.html
Solubility
10 mM in DMSO
Smiles
[Zerlasiran]
Molecular Weight
14155.81
References & Citations
[1]Rider DA, Eisermann M, Löffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240-247. |[2]Nissen SE, Wolski K, Watts GF, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2024;331(18):1534-1543.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-147425/Zerlasiran-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-147425/
Clinical Information
Phase 2
CAS Number
2646703-64-0
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RC202389L3V 200 µL
Frequenin (NCS1) (NM_014286) Human Tagged ORF Clone Lentiviral Particle
Ask
View Details 
